

## EARNINGS RELEASE 3Q14

São Paulo, November 6th, 2014. Raia Drogasil S.A. (BM\&FBovespa: RADL3) announces today its results for the $3^{\text {rd }}$ quarter of 2014 (3Q14). The consolidated quarterly information of Raia Drogasil S.A. for the period ended September $30^{\text {th }}, 2014$ was prepared in accordance with IFRS and was reviewed by our independent auditors in accordance with Brazilian and international standards of auditing. Such quarterly information was prepared in Reais and all growth rates are related to the same period of 2013.

As a result of the creation of RaiaDrogasil, we incurred both in 2014 and in 2013 on certain non-recurring expenses related to the integration. To facilitate a better understanding and analysis of our operating performance, we are supplementally presenting adjusted results for 2014 and 2013 excluding the effects of non-recurring expenses.

In April and in May of 2013 we recorded a reduction in social charges on labor, a line which was classified as part of Taxes, Discounts and Returns since it was calculated as a percentage of revenues. In order to maintain historical comparability, we reclassified such charges to Sales Expenses.

## HIGHLIGHTS:

- Drugstores: 1,045 stores in operation (33 openings and three closures)
- Gross Revenues: R\$ 2.0 billion, 18.3\% of growth (10.9\% for same-store sales)
- Gross Margin: 27.5\% of gross revenues, a 0.7 percentage point margin increase
- Adjusted EBITDA: R\$139.9 million, an EBITDA margin of 7.0\% and an increase of 54.1\%
- Adjusted Net Income: R\$80.5 million, a net margin of 4.0\% and an increase of 88.8\%
- Cash Flow: $\mathbf{R} \$ 22.4$ million positive free cash flow, $\mathbf{R} \$ \mathbf{2 9 . 0}$ million total cash flow

RADL3: R\$ 23.17/share
Number of Shares: $330,386,000$
Market Cap: R\$7,655 million
Closing: November $5^{\text {th }}, 2014$

IR Contacts:
Eugênio De Zagottis
Gabriel Rozenberg
Corina Steindler
Phone: +55 11 3769-7159
E-mail: ri@raiadrogasil.com.br

| Summary | 3Q13 | 4Q13 | 1Q14 | 2Q14 | 3Q14 |
| :---: | :---: | :---: | :---: | :---: | :---: |
| (R\$ thousand) |  |  |  |  |  |
| \# of Stores (end of period) | 931 | 967 | 986 | 1,015 | 1,045 |
| Store Openings | 29 | 41 | 18 | 29 | 33 |
| Store Closures | (6) | (4) | (1) | (2) | (3) |
| Net Reopenings/(Suspensions) | 2 | (1) | 2 | 2 | 0 |
| \# of Stores (average) | 920 | 950 | 977 | 1,003 | 1,032 |
| Head Count | 21,268 | 21,482 | 21,578 | 22,090 | 22,753 |
| Pharmacist Count | 3,260 | 3,322 | 3,451 | 3,587 | 3,747 |
| \# of Tickets | 34,567 | 34,803 | 34,078 | 36,078 | 37,536 |
| Gross Revenues | 1,682,958 | 1,738,649 | 1,718,910 | 1,856,576 | 1,990,328 |
| Gross Profit (Adjusted) | 451,785 | 464,412 | 462,109 | 522,254 | 548,200 |
| \% of Gross Revenues | 26.8\% | 26.7\% | 26.9\% | 28.1\% | 27.5\% |
| EBITDA (Adjusted) | 90,791 | 96,607 | 87,323 | 131,295 | 139,947 |
| \% of Gross Revenues | 5.4\% | 5.6\% | 5.1\% | 7.1\% | 7.0\% |
| Net Income (Adjusted) | 42,623 | 48,067 | 40,720 | 73,820 | 80,494 |
| \% of Gross Revenues | 2.5\% | 2.8\% | 2.4\% | 4.0\% | 4.0\% |
| Net Income | 18,618 | 27,818 | 29,131 | 62,120 | 67,979 |
| \% of Gross Revenues | 1.1\% | 1.6\% | 1.7\% | 3.3\% | 3.4\% |
| Free Cash Flow | 57,736 | 70,849 | $(118,953)$ | 51,479 | 22,446 | MERCADO



## STORE DEVELOPMENT

We opened 33 new stores and closed three, ending the quarter with 1,045 stores in operation. In the 9 M14 we opened a total of 80 stores. We reiterate our gross store opening guidance of 130 new stores for the year.


Does not include suspended stores, which have been temprarily closed to be rebranded

At the end of the period, $32.7 \%$ of our stores were still in the process of maturation, and had not yet reached their full potential in terms of revenues and profitability.

Our comparable national market share reached $9.3 \%$, a 0.4 percentage point increase when compared to the 3Q13. Our market share figures have been adjusted by IMS Health to exclude new informants to preserve historical comparability. Considering the inclusion of new informants, our national market share totaled 9.0\%.

We have increased our market share in all our regions. Our main highlight was São Paulo, where we recorded a 1.1 percentage point increase leveraged by our organic expansion and by the progressive recovery of one of our brands, which had lost market share in 2013. In the remaining states of the Southeast region, our market share increased by 0.1 percentage point, driven by the favorable performances in our stores, especially in Rio de Janeiro and in Espírito Santo.

In the Midwest region, we recorded a 0.9 percentage point increase due to strong performances in Mato Grosso do Sul, Mato Grosso and Distrito Federal, as well as in Goiás. We also recorded an excellent performance in the Southern region, where our market share increased by 0.6 percentage point, driven by store maturation in Paraná and in Santa Catarina and by or geographic expansion in Rio Grande do Sul.

Finally, our market share in the Northeast region reached $1.1 \%$, due to our growth in Bahia and to our recent entry in Pernambuco, Sergipe and Alagoas. It is important to highlight that we are further expanding our presence in the region through our entry in Paraíba (November $5^{\text {th }}$ ) and in Rio Grande do Norte (December).

## RaiaDrogasil



## GROSS REVENUES

 MERCADO
DMEROVISPA

## RaiaDrogasil

We ended the quarter with gross revenues of $R \$ 1,990.3$ million, an $18.3 \%$ increase over 2013.

The stores closed or suspended over the last twelve months have penalized our growth by 0.5 percentage point (18.8\% growth when excluding those stores from the comp base).

We recorded a sales growth of $10.9 \%$ for our same-store and of $6.1 \%$ for our mature stores. The quarter had a positive calendar effect of $0.7 \%$, which was fully offset by the negative impact of the World Cup in July, which penalized our growth also by 0.7 percentage point.

Our sales mix remained in line when compared to the 3Q13. The only variation recorded was a slight increase of 0.1 percentage point in generics at the expense of branded, which receded proportionally.


## GROSS PROFIT

We achieved a gross margin of $27.5 \%$ in the quarter, a 0.7 percentage point increase when compared to the 3Q13.

The return to the tax substitution regime in São Paulo in December 2013 relieved the tax burden we had experienced since the 3Q12, generating a positive impact of 0.4 percentage point. Additionally, we obtained better purchasing terms with suppliers and pursued tactical changes in pricing, which increased our gross margin by 0.3 percentage point.

## RaiaDrogasil

Gross Margin
( $\mathrm{R} \$$ million, \% of Gross Revenues)



SALES EXPENSES


Sales expenses totaled R\$ 362.3 million in the 3Q14, a 0.6 percentage point decrease over the previous year. We experienced a 0.2 percentage point dilution in payroll, mainly due to the slower pace of staff replenishment at the stores in July and in August. The annual salary readjustment, which occurs every July, was of $7.6 \%$ in 2014 versus $8.5 \%$ in 2013. Additionally, we recorded a 0.2 percentage point reduction in social charges due to one-off pressures recorded in the 3Q13.

Finally, the expense pressure from new stores amounted to only $0.2 \%$ of gross revenues, a 0.3 percentage point reduction over the 3Q13. This improvement was driven by the strong sales performance recorded in our recently opened stores and by the slightly slower pace of store openings in the 9 M 14 when compared to the previous year ( 80 stores versus 90 stores in the 9M13).

## GENERAL AND ADMINISTRATIVE EXPENSES

General and administrative expenses amounted to $\mathrm{R} \$ 46.0$ million, equivalent to $2.3 \%$ of gross revenues, a 0.3 percentage point dilution when compared to the previous year.

We experienced in the 3Q14 a reduction in our variable compensation allowance of approximately 0.2 percentage point in order to offset an excess provisioning that happened in the 1 H 14 related to our long-term incentive program based on restricted shares.

Non-recurring expenses amounted to $\mathrm{R} \$ 2.8$ million in the quarter.

General and Administrative Expenses


General and Administrative Expenses
(\% of Gross Revenues)


## EBITDA

We recorded an EBITDA of R\$ 139.9 million, a $54.1 \%$ increase over the 3Q13. The gross margin increase of 0.7 percentage point, combined with the 0.9 percentage point dilution in the SG\&A led to an EBITDA margin expansion of 1.6 percentage point.


New stores already opened in the year, as well as those that were in the opening process, reduced the EBITDA by R\$ 6.9 million in the 3Q14. Therefore, if we consider only the 965 stores in operation since the end of 2013 and the full absorption of logistics as well as of general and administrative expenses by such stores, our adjusted EBITDA would have totaled $R \$ 146.8$ million, equivalent to an EBITDA margin of $7.6 \%$ over the respective gross revenues.

## DEPRECIATION, NET FINANCIAL EXPENSES AND INCOME TAXES

Depreciation expenses totaled R\$ 48.3 million in the 3Q14, equivalent to $2.4 \%$ of gross revenues, and remained in line with the same period of the previous year.

We recorded a dilution in net financial expenses of 0.1 percentage point reflecting a lower level in net debt and interest as a percentage of gross revenues when compared to the previous year.

We booked $\mathrm{R} \$ 9.8$ million in taxes, equivalent to $0.5 \%$ of gross revenues, a 0.2 percentage point increase, thus reflecting the improvement in our profitability when compared to the previous year. This amount includes the tax shield of the goodwill amortization effect of $\mathrm{R} \$ 10.7$ million.

## RaiaDrogasil

$\qquad$
$\qquad$
Net Financial Expenses
Taxes Accrued
( $\mathrm{R} \$$ million, \% of Gross Revenues)
( $\mathrm{R} \$$ million, \% of Gross Revenues)
( $\mathrm{R} \$$ million, \% of Gross Revenues)


ADJUSTED NET INCOME
 MERCADO

We recorded an adjusted net income of R\$ 80.5 million, an $88.8 \%$ increase over the 3Q13, equivalent to an adjusted net margin of $4.0 \%$. This 1.5 percentage point margin improvement over the 3Q13 stemmed from a 1.6 percentage point increase in our EBITDA margin combined with a reduction in financial expenses of 0.1 percentage point and partially offset by an income tax increase of 0.2 percentage point.

It is important to highlight that our reported net income (after non-recurring expenses and not including the tax shield from goodwill amortization) increased $265.1 \%$ over the previous year due to the previously mentioned operating and financial improvements as well as to a radical reduction in non-recurring expenses.

## CASH CYCLE

We ended the quarter with a cash cycle reduction of 1.3 day when compared to the 3Q13.


We recorded an increase in inventories of 10.2 days. Taxes on inventories arising from our return to the tax substitution regime in the 4Q13 increased our days of inventories by 4.5 days. Therefore, on a comparable basis, we recorded an increase of 5.7 days versus the 3Q13, when a reduction in our purchases to decrease excess inventories of generics had reduced our inventories days. Additionally, accounts payable increased by 12.1 days due to the week comp base of the 3Q13, when the lack of generation of new generics invoices penalized accounts payable.

Finally, receivables increased by 0.7 day when compared to the previous year.

## CASH FLOW

We generated a positive free cash flow of $\mathrm{R} \$ 22.4$ million in the quarter. Our operating cash flow ( $\mathrm{R} \$ 87.0$ million) has fully financed the investments ( $\mathrm{R} \$ 64.6$ million) undertaken in the period.

| Cash Flow | 3Q14 | 3Q13 | 9M14 | 9M13 |
| :---: | :---: | :---: | :---: | :---: |
| (RS million) |  |  |  |  |
| Adjusted EBIT | 91.6 | 49.6 | 222.6 | 144.1 |
| Non-Recurring Expenses | (2.8) | (20.2) | (5.6) | (34.0) |
| Income Tax (34\%) | (30.2) | (10.0) | (73.8) | (37.4) |
| Taxshield from Goodwill Amortization | 10.7 | 12.1 | 32.1 | 19.7 |
| Depreciation | 48.3 | 41.2 | 136.0 | 116.3 |
| Others | (8.6) | (5.7) | (6.2) | 9.7 |
| Resources from Operations | 109.1 | 67.1 | 305.0 | 218.3 |
| Cash Cycle* | (49.7) | 30.4 | (192.6) | (121.4) |
| Other Assets (Liabilities) | 27.7 | 23.6 | 29.9 | 52.8 |
| Operating Cash Flow | 87.0 | 121.1 | 142.3 | 149.7 |
| Investments | (64.6) | (63.4) | (187.4) | (175.3) |
| Free Cash Flow | 22.4 | 57.7 | (45.0) | (25.6) |
| Interest on Equity | - | - | (17.0) | (13.0) |
| Net Financial Expenses | (1.3) | (2.6) | (5.7) | (9.3) |
| Share Buyback | - | - | (20.9) | - |
| Income Tax (Tax benefit over financial expenses and interest on equity) | 7.9 | 2.8 | 19.3 | 11.6 |
| Total Cash Flow | 29.0 | 57.9 | (69.3) | (36.2) |

* Cash cycle includes variation in accounts receivables, inventories and suppliers
** Does not include financing cash flow

Resources from operations amounted to $\mathrm{R} \$ 109.1$ million, equivalent to $5.5 \%$ of our gross revenues, while working capital employed totaled $\mathrm{R} \$ 22.0$ million, resulting in an operating cash flow of $\mathrm{R} \$ 87.0$ million in the period.

Fixed asset investments amounted to $\mathrm{R} \$ 64.6$ million versus $\mathrm{R} \$ 63.4$ million in the same period of 2013 , including $\mathrm{R} \$$ 41.2 million in new store openings, $\mathrm{R} \$ 13.1$ million in existing stores renovation, and $\mathrm{R} \$ 10.3$ million in infrastructure.

We generated a total cash flow of $\mathrm{R} \$ 29.0$ million in the 3Q14, including $\mathrm{R} \$ 1.3$ million in net financial expenses, which was fully offset by the tax shield of $\mathrm{R} \$ 7.9$ million in the period.

In the 9M14, we recorded a free cash flow consumption of $\mathrm{R} \$ 45.0$ million and a total cash flow consumption of $\mathrm{R} \$ 69.3$ million, both due to the favorable cash cycle seasonality recorded in December, that penalizes the comparison with every other month of the year.

Finally, we accrued $\mathrm{R} \$ 22.0$ million in interest on equity in the quarter.

## INDEBTEDNESS

At the end of the quarter, our net debt amounted to $\mathrm{R} \$ 72.2$ million versus $\mathrm{R} \$ 61.4$ million recorded in the same period of the previous year.

Our gross debt totaled R\$222.0 million, of which $100 \%$ is comprised by BNDES (Brazilian Economic and Social Development Bank) lines. Of our total indebtedness, $55.5 \%$ is long-term while $44.5 \%$ relates to the short-term parcels of our long-term debt. We ended the quarter with a total cash position (cash and marketable securities) of R\$149.8 million.

## CAPITAL MARKETS

Considering our share price of $\mathrm{R} \$ 20.94$ on September $30^{\text {th }}$, we have posted a return of $41.7 \%$ in the year, 36.6 percentage points above the IBOVESPA, which increased by $5.1 \%$ over the same period.


In the 3Q14, our average daily trading volume was of $\mathrm{R} \$ 18.0$ million.
Since the IPO of Drogasil, we achieved a cumulative increase of $273.9 \%$ when compared to a negative return of $0.5 \%$ of the IBOVESPA over the same period, a compound annual return of $19.9 \%$.

Considering the IPO of Raia in December of 2010, the cumulative return in the period amounted to $99.9 \%$ when compared to a decrease of $20.4 \%$ by the IBOVESPA, a compound annual return of $20.1 \%$. These figures do not include dividends and interest on equity paid over the period.

## RaiaDrogasil

Adjusted Income Statement
( $R \$$ thousand)
Gross Revenues

Taxes, Discounts and Returns

## Net Revenues

Cost of Goods Sold

## Gross Profit

Operational (Expenses) Revenues Sales

General and Administrative
Other Operational Expenses, Net
Operational Expenses

EBITDA

Depreciation and Amortization

Operational Earnings before Financial Results

Financial Expenses
Financial Revenues
Financial Expenses/Revenues

Earnings before Income Tax and Social Charges

Income Tax and Social Charges

Net Income

| 3Q13 | 3Q14 | 9 M 13 | 9M14 |
| :---: | :---: | :---: | :---: |
| 1,682,958 | 1,990,328 | 4,725,454 | 5,565,813 |
| $(57,421)$ | $(67,998)$ | $(161,785)$ | $(193,978)$ |
| 1,625,537 | 1,922,329 | 4,563,670 | 5,371,835 |
| $(1,173,752)$ | $(1,374,129)$ | $(3,295,785)$ | $(3,839,272)$ |
| 451,785 | 548,200 | 1,267,885 | 1,532,563 |
| $(317,061)$ | $(362,287)$ | $(878,616)$ | $(1,026,746)$ |
| $(43,933)$ | $(45,967)$ | $(128,841)$ | $(147,253)$ |
| $(360,994)$ | $(408,254)$ | $(1,007,457)$ | $(1,173,999)$ |
| 90,791 | 139,947 | 260,428 | 358,564 |
| $(41,220)$ | $(48,300)$ | $(116,290)$ | $(135,964)$ |
| 49,571 | 91,647 | 144,138 | 222,600 |
| $(4,823)$ | $(6,227)$ | $(15,335)$ | $(19,139)$ |
| 2,183 | 4,878 | 6,033 | 13,477 |
| $(2,640)$ | $(1,349)$ | $(9,302)$ | $(5,662)$ |
| 46,931 | 90,297 | 134,836 | 216,939 |
| $(4,308)$ | $(9,803)$ | $(7,093)$ | $(21,904)$ |
| 42,623 | 80,494 | 127,743 | 195,034 |

## RaiaDrogasil

Income Statemen
( $R S$ thousand)
Gross Revenues
Taxes, Discounts and Returns

## Net Revenues

Cost of Goods Sold

## Gross Profit

Operational (Expenses) Revenues
Sales
General and Administrative
Other Operational Expenses, Net
Operational Expenses

## EBITDA

Depreciation and Amortization

Operational Earnings before Financial Results
Financial Expenses
Financial Revenues
Financial Expenses/Revenues

Earnings before Income Tax and Social Charges

Income Tax and Social Charges

## Net Income

| 3Q13 | 3Q14 | 9 M 13 | 9M14 |
| :---: | :---: | :---: | :---: |
| 1,682,958 | 1,990,328 | 4,725,454 | 5,565,813 |
| $(57,421)$ | $(67,998)$ | $(172,506)$ | $(193,978)$ |
| 1,625,537 | 1,922,329 | 4,552,948 | 5,371,835 |
| $(1,173,752)$ | $(1,374,129)$ | $(3,297,184)$ | $(3,839,272)$ |
| 451,785 | 548,200 | 1,255,764 | 1,532,563 |
| $(322,162)$ | $(362,287)$ | $(867,435)$ | $(1,026,746)$ |
| $(44,694)$ | $(45,967)$ | $(129,300)$ | $(147,253)$ |
| $(14,300)$ | $(2,754)$ | $(32,595)$ | $(5,622)$ |
| $(381,156)$ | $(411,007)$ | $(1,029,330)$ | (1,179,621) |
| 70,629 | 137,193 | 226,434 | 352,942 |
| $(41,220)$ | $(48,300)$ | $(116,290)$ | $(135,964)$ |
| 29,409 | 88,893 | 110,144 | 216,978 |
| $(4,823)$ | $(6,227)$ | $(15,336)$ | $(19,139)$ |
| 2,183 | 4,878 | 6,033 | 13,477 |
| $(2,640)$ | $(1,349)$ | $(9,303)$ | $(5,662)$ |
| 26,769 | 87,544 | 100,841 | 211,317 |
| $(8,151)$ | $(19,565)$ | $(27,674)$ | $(52,087)$ |
| 18,618 | 67,979 | 73,167 | 159,230 |


| Assets | 3Q13 | 3Q14 |
| :---: | :---: | :---: |
| (R\$ thousand) |  |  |
| Current Assets |  |  |
| Cash and Cash Equivalents | 122,367 | 149,768 |
| Accounts Receivable | 364,639 | 445,430 |
| Inventories | 948,534 | 1,264,466 |
| Taxes Receivable | 58,136 | 38,060 |
| Other Accounts Receivable | 96,374 | 121,493 |
| Following Fiscal Year Expenses | 11,889 | 10,861 |
|  | 1,601,939 | 2,030,078 |
| Non-Current Assets |  |  |
| Deposit in Court | 10,276 | 12,649 |
| Taxes Receivable | 11,202 | 15,585 |
| Other Credits | 715 | 876 |
| Property, Plant and Equipment | 518,411 | 609,690 |
| Intangible | 1,156,102 | 1,130,070 |
|  | 1,696,706 | 1,768,870 |
| ASSETS | 3,298,645 | 3,798,948 |


| Liabilities and Shareholder's Equity | 3 Q 13 | 3Q14 |
| :---: | :---: | :---: |
| (R\$ thousand) |  |  |
| Current |  |  |
| Suppliers | 445,899 | 704,648 |
| Loans and Financing | 79,878 | 98,756 |
| Salaries and Social Charges Payable | 139,259 | 173,499 |
| Taxes Payable | 39,721 | 38,350 |
| Dividend and Interest on Equity | 22,049 | 44,429 |
| Provision for Lawsuits | 4,948 | 5,188 |
| Other Accounts Payable | 58,884 | 77,285 |
|  | 790,638 | 1,142,154 |
| Non-Current Assets |  |  |
| Loans and Financing | 103,933 | 123,243 |
| Provision for Lawsuits | 8,463 | 8,943 |
| Income Tax and Social Charges deferred | 87,876 | 115,159 |
| Other Accounts Payable | 2,868 | 3,294 |
|  | 203,140 | 250,640 |
| Shareholder's Equity |  |  |
| Common Stock | 908,639 | 908,639 |
| Capital Reserves | 1,039,935 | 1,019,037 |
| Revaluation Reserve | 12,988 | 12,802 |
| Income Reserves | 294,721 | 357,169 |
| Accrued Income | 48,584 | 108,507 |
|  | 2,304,867 | 2,406,154 |
| LIABILITIES AND SHAREHOLDERS' EQUITY | 3,298,645 | 3,798,948 |


|  | 3Q13 | 3Q14 | 9 M 13 | 9M14 |
| :---: | :---: | :---: | :---: | :---: |
| Cash Flow |  |  |  |  |
| Earnings before Income Tax and Social Charges | 26,769 | 87,544 | 100,841 | 211,317 |
| Adjustments |  |  |  |  |
| Depreciations and Amortization | 41,220 | 48,300 | 116,290 | 135,964 |
| P,P\&E and Intangible Assets residual value | 2,723 | 259 | 4,661 | 684 |
| Provisioned Lawsuits | 114 | (845) | 2,329 | 2,222 |
| Provisioned Inventories Loss | (237) | 2,441 | 9,413 | 5,004 |
| Allowance for Doubtful Accounts | (469) | $(1,502)$ | $(1,246)$ | (762) |
| Provisioned Store Closures |  |  |  | 3,081 |
| Interest Expenses | 4,154 | 5,670 | 12,943 | 18,035 |
|  | 74,274 | 141,867 | 245,231 | 375,545 |
| Assets and Liabilities variation |  |  |  |  |
| Accounts Receivable | 13,769 | $(30,145)$ | $(7,189)$ | $(83,951)$ |
| Inventories | 60,148 | $(95,361)$ | 15,448 | $(136,848)$ |
| Other Short Term Assets | 13,559 | $(5,688)$ | 35,780 | 724 |
| Long Term Assets | 2,282 | $(2,231)$ | 8,092 | $(5,757)$ |
| Suppliers | $(43,491)$ | 75,792 | $(129,688)$ | 28,224 |
| Salaries and Social Charges | 28,065 | 20,710 | 46,362 | 57,147 |
| Taxes Payable | $(7,448)$ | 2,655 | $(5,408)$ | $(29,589)$ |
| Other Liabilities | $(13,321)$ | 4,091 | $(35,450)$ | $(2,431)$ |
| Rent Payable | 477 | 8,141 | 3,412 | 9,804 |
| Cash from Operations | 128,314 | 119,831 | 176,590 | 212,868 |
| Income Tax and Social Charges Paid | $(2,918)$ | $(20,531)$ | $(11,629)$ | $(38,866)$ |
| Net Cash from (invested) Operational Activities | 125,396 | 99,300 | 164,961 | 174,002 |
| Investment Activities Cash Flow |  |  |  |  |
| P,P\&E and Intangible Acquisitions | $(64,564)$ | $(64,594)$ | $(176,648)$ | $(188,164)$ |
| P, P\&E Sale Payments | 1,186 |  | 1,383 | 793 |
| Net Cash from Investment Activities | $(63,378)$ | $(64,594)$ | $(175,265)$ | $(187,371)$ |
| Financing Activities Cash Flow |  |  |  |  |
| Funding |  |  | 26,121 | 37,703 |
| Payments | $(13,112)$ | $(23,921)$ | $(40,800)$ | $(63,455)$ |
| Interest Paid | (96) | $(4,525)$ | $(6,625)$ | $(15,112)$ |
| Share Buyback |  |  |  | $(20,898)$ |
| Interest on Equity and Dividends Paid |  |  | $(12,988)$ | $(16,986)$ |
| Net Cash from Funding Activities | $(13,208)$ | $(28,446)$ | $(34,292)$ | $(78,748)$ |
| Cash and Cash Equivalents net increase | 48,810 | 6,260 | $(44,596)$ | $(92,117)$ |
| Cash and Cash Equivalents in the beggining of the period | 73,557 | 143,508 | 166,963 | 241,885 |
| Cash and Cash Equivalents in the end of the period | 122,367 | 149,768 | 122,367 | 149,768 |

Portuguese
at 10:00 am (Brasília) / 7:00 am (NY)
Dial in access:
+55 (11) 2188-0155
Conference ID: Raia Drogasil
Replay (available 'til 11/14/2014):
+55 (11) 2188-0400

English
at 12:00 pm (Brasília) / 9:00 am (NY)
Dial in access:
+1 (646) 843-6054
+55 (11) 2188-0155
Conference ID: Raia Drogasil
Replay (available 'til 11/14/2014):
+55 (11) 2188-0400

Live broadcast through the internet at: www.raiadrogasil.com.br/ir
For more information, please contact our Investor Relations department.
E-mail: ri@raiadrogasil.com.br

